首页 > 最新文献

Nature Reviews Gastroenterology &Hepatology最新文献

英文 中文
Digital twins are integral to personalizing medicine and improving public health 数字双胞胎是个性化医疗和改善公共卫生不可或缺的一部分
IF 45.9 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-10-09 DOI: 10.1038/s41575-024-00992-3
Brian Johnson, Kit Curtius
Digital twins provide a framework to advance the field of personalized medicine by generating clinically actionable strategies that leverage individualized data as well as current and emerging research. Strong interdisciplinary teamwork, specific funding mechanisms and integration of key biological details such as somatic evolution are necessary for the effective adoption of digital twins in medicine.
数字孪生提供了一个框架,通过利用个体化数据以及当前和新兴的研究,产生临床上可操作的策略,从而推动个性化医疗领域的发展。要在医学中有效采用数字孪生技术,就必须要有强大的跨学科团队合作、特定的资助机制以及关键生物细节(如体细胞进化)的整合。
{"title":"Digital twins are integral to personalizing medicine and improving public health","authors":"Brian Johnson, Kit Curtius","doi":"10.1038/s41575-024-00992-3","DOIUrl":"10.1038/s41575-024-00992-3","url":null,"abstract":"Digital twins provide a framework to advance the field of personalized medicine by generating clinically actionable strategies that leverage individualized data as well as current and emerging research. Strong interdisciplinary teamwork, specific funding mechanisms and integration of key biological details such as somatic evolution are necessary for the effective adoption of digital twins in medicine.","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":null,"pages":null},"PeriodicalIF":45.9,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142385079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interpreting modern randomized controlled trials of medical therapy in inflammatory bowel disease 解读炎症性肠病医学疗法的现代随机对照试验
IF 45.9 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-10-08 DOI: 10.1038/s41575-024-00989-y
Christopher Ma, Vipul Jairath, Brian G. Feagan, Laurent Peyrin-Biroulet, Silvio Danese, Bruce E. Sands, Remo Panaccione
Treatment options for the medical management of inflammatory bowel disease (IBD) have expanded substantially over the past decade. Multiple classes of advanced therapies, including both monoclonal antibodies and novel oral small molecules, are now available for the treatment of moderately-to-severely active Crohn’s disease and ulcerative colitis, highlighted by the approvals of the first IL23p19 antagonists, selective Janus kinase inhibitors and sphingosine-1-phosphate receptor modulators. These advances have been accompanied by the identification of novel targets and the rapid growth in both the number and size of IBD clinical trials. Over a dozen landmark randomized controlled trials (RCTs) have been completed in the past 5 years, including the first head-to-head biologic trials, the first combination biologic studies, and multiple phase III registrational trials of novel compounds with new co-primary and composite end points that will change the treatment landscape for years to come. Importantly, the methodology of RCTs in IBD has evolved substantially, with new trial designs, evaluation of unique patient populations, and different types of efficacy and safety end points being key innovations. In this Review, we provide a comprehensive evaluation of how modern RCTs of IBD medical therapies have evolved and the implications for their appraisal that will help guide the application of these data to clinical practice. In this Review, Ma and colleagues discuss the evolution in clinical trial designs for inflammatory bowel disease (IBD), their implications for clinical care, and identify future directions for the next generation of IBD studies.
在过去的十年中,炎症性肠病(IBD)的治疗方案大幅增加。目前,包括单克隆抗体和新型口服小分子药物在内的多类先进疗法已可用于治疗中度至重度活动性克罗恩病和溃疡性结肠炎,首批 IL23p19 拮抗剂、选择性 Janus 激酶抑制剂和鞘氨醇-1-磷酸受体调节剂的获批更是其中的亮点。在取得这些进展的同时,我们还发现了新的靶点,IBD 临床试验的数量和规模也在迅速增长。过去 5 年中完成了十多项具有里程碑意义的随机对照试验 (RCT),其中包括首例头对头生物制剂试验、首例联合生物制剂研究以及多项新型化合物 III 期注册试验,这些试验采用了新的共同主要终点和复合终点,将在未来数年内改变治疗格局。重要的是,IBD 的 RCT 方法已经发生了重大变化,新的试验设计、对独特患者群体的评估以及不同类型的疗效和安全性终点都是重要的创新。在本综述中,我们将全面评估 IBD 医学疗法的现代 RCT 如何演变以及对其评估的影响,这将有助于指导临床实践中对这些数据的应用。
{"title":"Interpreting modern randomized controlled trials of medical therapy in inflammatory bowel disease","authors":"Christopher Ma, Vipul Jairath, Brian G. Feagan, Laurent Peyrin-Biroulet, Silvio Danese, Bruce E. Sands, Remo Panaccione","doi":"10.1038/s41575-024-00989-y","DOIUrl":"10.1038/s41575-024-00989-y","url":null,"abstract":"Treatment options for the medical management of inflammatory bowel disease (IBD) have expanded substantially over the past decade. Multiple classes of advanced therapies, including both monoclonal antibodies and novel oral small molecules, are now available for the treatment of moderately-to-severely active Crohn’s disease and ulcerative colitis, highlighted by the approvals of the first IL23p19 antagonists, selective Janus kinase inhibitors and sphingosine-1-phosphate receptor modulators. These advances have been accompanied by the identification of novel targets and the rapid growth in both the number and size of IBD clinical trials. Over a dozen landmark randomized controlled trials (RCTs) have been completed in the past 5 years, including the first head-to-head biologic trials, the first combination biologic studies, and multiple phase III registrational trials of novel compounds with new co-primary and composite end points that will change the treatment landscape for years to come. Importantly, the methodology of RCTs in IBD has evolved substantially, with new trial designs, evaluation of unique patient populations, and different types of efficacy and safety end points being key innovations. In this Review, we provide a comprehensive evaluation of how modern RCTs of IBD medical therapies have evolved and the implications for their appraisal that will help guide the application of these data to clinical practice. In this Review, Ma and colleagues discuss the evolution in clinical trial designs for inflammatory bowel disease (IBD), their implications for clinical care, and identify future directions for the next generation of IBD studies.","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":null,"pages":null},"PeriodicalIF":45.9,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41575-024-00989-y.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142384301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Classifying compounds as prebiotics — scientific perspectives and recommendations 将化合物分类为益生元--科学视角和建议
IF 65.1 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-10-02 DOI: 10.1038/s41575-024-00981-6
Robert Hutkins, Jens Walter, Glenn R. Gibson, Cassandre Bedu-Ferrari, Karen Scott, Daniel J. Tancredi, Anisha Wijeyesekera, Mary Ellen Sanders

Microbiomes provide key contributions to health and potentially important therapeutic targets. Conceived nearly 30 years ago, the prebiotic concept posits that targeted modulation of host microbial communities through the provision of selectively utilized growth substrates provides an effective approach to improving health. Although the basic tenets of this concept remain the same, it is timely to address certain challenges pertaining to prebiotics, including establishing that prebiotic-induced microbiota modulation causes the health outcome, determining which members within a complex microbial community directly utilize specific substrates in vivo and when those microbial effects sufficiently satisfy selectivity requirements, and clarification of the scientific principles on which the term ‘prebiotic’ is predicated to inspire proper use. In this Expert Recommendation, we provide a framework for the classification of compounds as prebiotics. We discuss ecological principles by which substrates modulate microbiomes and methodologies useful for characterizing such changes. We then propose statistical approaches that can be used to establish causal links between selective effects on the microbiome and health effects on the host, which can help address existing challenges. We use this information to provide the minimum criteria needed to classify compounds as prebiotics. Furthermore, communications to consumers and regulatory approaches to prebiotics worldwide are discussed.

微生物群对健康有重要贡献,也可能是重要的治疗目标。近 30 年前提出的益生元概念认为,通过提供选择性利用的生长基质,有针对性地调节宿主微生物群落,是改善健康的有效方法。虽然这一概念的基本原理没有改变,但现在是解决益生元相关挑战的时候了,这些挑战包括:确定益生元诱导的微生物群调节会导致健康结果;确定复杂微生物群落中哪些成员在体内直接利用特定底物,以及这些微生物效应何时足以满足选择性要求;澄清 "益生元 "这一术语所依据的科学原则,以便正确使用。在本专家建议中,我们为益生元化合物的分类提供了一个框架。我们讨论了底物调节微生物组的生态学原理以及表征此类变化的有用方法。然后,我们提出了统计方法,可用于建立微生物组的选择性效应与对宿主健康的影响之间的因果联系,这有助于应对现有的挑战。我们利用这些信息提供了将化合物归类为益生元所需的最低标准。此外,我们还讨论了与消费者的沟通以及全球对益生元的监管方法。
{"title":"Classifying compounds as prebiotics — scientific perspectives and recommendations","authors":"Robert Hutkins, Jens Walter, Glenn R. Gibson, Cassandre Bedu-Ferrari, Karen Scott, Daniel J. Tancredi, Anisha Wijeyesekera, Mary Ellen Sanders","doi":"10.1038/s41575-024-00981-6","DOIUrl":"https://doi.org/10.1038/s41575-024-00981-6","url":null,"abstract":"<p>Microbiomes provide key contributions to health and potentially important therapeutic targets. Conceived nearly 30 years ago, the prebiotic concept posits that targeted modulation of host microbial communities through the provision of selectively utilized growth substrates provides an effective approach to improving health. Although the basic tenets of this concept remain the same, it is timely to address certain challenges pertaining to prebiotics, including establishing that prebiotic-induced microbiota modulation causes the health outcome, determining which members within a complex microbial community directly utilize specific substrates in vivo and when those microbial effects sufficiently satisfy selectivity requirements, and clarification of the scientific principles on which the term ‘prebiotic’ is predicated to inspire proper use. In this Expert Recommendation, we provide a framework for the classification of compounds as prebiotics. We discuss ecological principles by which substrates modulate microbiomes and methodologies useful for characterizing such changes. We then propose statistical approaches that can be used to establish causal links between selective effects on the microbiome and health effects on the host, which can help address existing challenges. We use this information to provide the minimum criteria needed to classify compounds as prebiotics. Furthermore, communications to consumers and regulatory approaches to prebiotics worldwide are discussed.</p>","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":null,"pages":null},"PeriodicalIF":65.1,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142363258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MASLD: a disease in flux MASLD:变化中的疾病
IF 45.9 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-10-02 DOI: 10.1038/s41575-024-00990-5
Alina M. Allen, Juan Pablo Arab, Vincent Wai-Sun Wong
To coincide with the 20th anniversary of Nature Reviews Gastroenterology & Hepatology, we asked three experts to reflect on the past, present and future of metabolic dysfunction-associated steatotic liver disease (MASLD) research and clinical management. They comment on how MASLD research and clinical management has changed over the past 20 years, the strengths and limitations of the MASLD field today, and their predictions for progress over the next 20 years. In this Viewpoint, Alina M. Allen, Juan Pablo Arab and Vincent Wai-Sun Wong reflect on the past, present and future of metabolic dysfunction-associated steatotic liver disease (MASLD) research and clinical management.
在《Nature Reviews Gastroenterology & Hepatology》杂志创刊 20 周年之际,我们请三位专家回顾了代谢功能障碍相关性脂肪肝 (MASLD) 研究和临床管理的过去、现在和未来。他们评论了过去 20 年来 MASLD 研究和临床管理的变化、当今 MASLD 领域的优势和局限性,以及他们对未来 20 年进展的预测。在本视点中,Alina M. Allen、Juan Pablo Arab 和 Vincent Wai-Sun Wong 回顾了代谢功能障碍相关性脂肪肝(MASLD)研究和临床管理的过去、现在和未来。
{"title":"MASLD: a disease in flux","authors":"Alina M. Allen,&nbsp;Juan Pablo Arab,&nbsp;Vincent Wai-Sun Wong","doi":"10.1038/s41575-024-00990-5","DOIUrl":"10.1038/s41575-024-00990-5","url":null,"abstract":"To coincide with the 20th anniversary of Nature Reviews Gastroenterology &amp; Hepatology, we asked three experts to reflect on the past, present and future of metabolic dysfunction-associated steatotic liver disease (MASLD) research and clinical management. They comment on how MASLD research and clinical management has changed over the past 20 years, the strengths and limitations of the MASLD field today, and their predictions for progress over the next 20 years. In this Viewpoint, Alina M. Allen, Juan Pablo Arab and Vincent Wai-Sun Wong reflect on the past, present and future of metabolic dysfunction-associated steatotic liver disease (MASLD) research and clinical management.","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":null,"pages":null},"PeriodicalIF":45.9,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41575-024-00990-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142363007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dietary and metabolic effects on intestinal stem cells in health and disease 饮食和新陈代谢对健康和疾病中肠干细胞的影响
IF 65.1 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-10-02 DOI: 10.1038/s41575-024-00980-7
Jessica E. S. Shay, Ömer H. Yilmaz

Diet and nutritional metabolites exhibit wide-ranging effects on health and disease partly by altering tissue composition and function. With rapidly rising rates of obesity, there is particular interest in how obesogenic diets influence tissue homeostasis and risk of tumorigenesis; epidemiologically, these diets have a positive correlation with various cancers, including colorectal cancer. The gastrointestinal tract is a highly specialized, continuously renewing tissue with a fundamental role in nutrient uptake and is, in turn, influenced by diet composition and host metabolic state. Intestinal stem cells are found at the base of the intestinal crypt and can generate all mature lineages that comprise the intestinal epithelium and are uniquely influenced by host diet, metabolic by-products and energy dynamics. Similarly, tumour growth and metabolism can also be shaped by nutrient availability and host diet. In this Review, we discuss how different diets and metabolic changes influence intestinal stem cells in homeostatic and pathological conditions, as well as tumorigenesis. We also discuss how dietary changes and composition affect the intestinal epithelium and its surrounding microenvironment.

饮食和营养代谢物通过改变组织的组成和功能,对健康和疾病产生了广泛的影响。随着肥胖率的迅速上升,人们对肥胖饮食如何影响组织稳态和肿瘤发生风险尤为关注;从流行病学角度看,这些饮食与包括结直肠癌在内的各种癌症呈正相关。胃肠道是一个高度特化、不断更新的组织,在营养摄取方面发挥着重要作用,反过来又受到饮食成分和宿主代谢状态的影响。肠干细胞存在于肠隐窝底部,可生成构成肠上皮的所有成熟细胞系,并受到宿主饮食、代谢副产物和能量动态的独特影响。同样,肿瘤的生长和新陈代谢也会受到营养供应和宿主饮食的影响。在这篇综述中,我们将讨论不同饮食和代谢变化如何影响肠道干细胞的平衡和病理状态以及肿瘤发生。我们还将讨论饮食变化和组成如何影响肠上皮细胞及其周围微环境。
{"title":"Dietary and metabolic effects on intestinal stem cells in health and disease","authors":"Jessica E. S. Shay, Ömer H. Yilmaz","doi":"10.1038/s41575-024-00980-7","DOIUrl":"https://doi.org/10.1038/s41575-024-00980-7","url":null,"abstract":"<p>Diet and nutritional metabolites exhibit wide-ranging effects on health and disease partly by altering tissue composition and function. With rapidly rising rates of obesity, there is particular interest in how obesogenic diets influence tissue homeostasis and risk of tumorigenesis; epidemiologically, these diets have a positive correlation with various cancers, including colorectal cancer. The gastrointestinal tract is a highly specialized, continuously renewing tissue with a fundamental role in nutrient uptake and is, in turn, influenced by diet composition and host metabolic state. Intestinal stem cells are found at the base of the intestinal crypt and can generate all mature lineages that comprise the intestinal epithelium and are uniquely influenced by host diet, metabolic by-products and energy dynamics. Similarly, tumour growth and metabolism can also be shaped by nutrient availability and host diet. In this Review, we discuss how different diets and metabolic changes influence intestinal stem cells in homeostatic and pathological conditions, as well as tumorigenesis. We also discuss how dietary changes and composition affect the intestinal epithelium and its surrounding microenvironment.</p>","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":null,"pages":null},"PeriodicalIF":65.1,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142363003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapy affects tumour microenvironment in pancreatic cancer 治疗会影响胰腺癌的肿瘤微环境
IF 45.9 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-10-01 DOI: 10.1038/s41575-024-00999-w
Eleni Kotsiliti
{"title":"Therapy affects tumour microenvironment in pancreatic cancer","authors":"Eleni Kotsiliti","doi":"10.1038/s41575-024-00999-w","DOIUrl":"10.1038/s41575-024-00999-w","url":null,"abstract":"","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":null,"pages":null},"PeriodicalIF":45.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142330385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tuft cells in the intestine, immunity and beyond 肠道中的簇细胞、免疫力及其他
IF 65.1 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-26 DOI: 10.1038/s41575-024-00978-1
Xiaogang Feng, Pascal Flüchter, Jeshua C. De Tenorio, Christoph Schneider

Tuft cells have gained substantial attention over the past 10 years due to numerous reports linking them with type 2 immunity and microorganism-sensing capacity in many mucosal tissues. This heightened interest is fuelled by their unique ability to produce an array of biological effector molecules, including IL-25, allergy-related eicosanoids, and the neurotransmitter acetylcholine, enabling downstream responses in diverse cell types. Operating through G protein-coupled receptor-mediated signalling pathways reminiscent of type II taste cells in oral taste buds, tuft cells emerge as chemosensory sentinels that integrate luminal conditions, eliciting appropriate responses in immune, epithelial and neuronal populations. How tuft cells promote tissue alterations and adaptation to the variety of stimuli at mucosal surfaces has been explored in multiple studies in the past few years. Since the initial recognition of the role of tuft cells, the discovery of diverse tuft cell effector functions and associated feedback loops have also revealed the complexity of tuft cell biology. Although earlier work largely focused on extraintestinal tissues, novel genetic tools and recent mechanistic studies on intestinal tuft cells established fundamental concepts of tuft cell activation and functions. This Review is an overview of intestinal tuft cells, providing insights into their development, signalling and interaction modules in immunity and other states.

在过去的 10 年中,簇状细胞受到了广泛关注,因为有大量报道称簇状细胞与许多粘膜组织的 2 型免疫和微生物感应能力有关。它们能产生一系列生物效应分子,包括 IL-25、与过敏相关的类二十烷酸和神经递质乙酰胆碱,从而在不同类型的细胞中产生下游反应。簇细胞通过 G 蛋白偶联受体介导的信号通路运作,让人联想到口腔味蕾中的 II 型味觉细胞,簇细胞作为化学感觉哨兵整合腔内条件,引起免疫、上皮和神经元群体的适当反应。在过去几年中,多项研究探讨了簇细胞如何促进组织改变和适应粘膜表面的各种刺激。自最初认识到丛细胞的作用以来,对丛细胞多种效应器功能和相关反馈回路的发现也揭示了丛细胞生物学的复杂性。虽然早期的工作主要集中在肠外组织,但新型遗传工具和最近对肠道簇细胞的机理研究确立了簇细胞活化和功能的基本概念。本综述概述了肠簇细胞,深入探讨了它们在免疫和其他状态下的发育、信号传递和相互作用模块。
{"title":"Tuft cells in the intestine, immunity and beyond","authors":"Xiaogang Feng, Pascal Flüchter, Jeshua C. De Tenorio, Christoph Schneider","doi":"10.1038/s41575-024-00978-1","DOIUrl":"https://doi.org/10.1038/s41575-024-00978-1","url":null,"abstract":"<p>Tuft cells have gained substantial attention over the past 10 years due to numerous reports linking them with type 2 immunity and microorganism-sensing capacity in many mucosal tissues. This heightened interest is fuelled by their unique ability to produce an array of biological effector molecules, including IL-25, allergy-related eicosanoids, and the neurotransmitter acetylcholine, enabling downstream responses in diverse cell types. Operating through G protein-coupled receptor-mediated signalling pathways reminiscent of type II taste cells in oral taste buds, tuft cells emerge as chemosensory sentinels that integrate luminal conditions, eliciting appropriate responses in immune, epithelial and neuronal populations. How tuft cells promote tissue alterations and adaptation to the variety of stimuli at mucosal surfaces has been explored in multiple studies in the past few years. Since the initial recognition of the role of tuft cells, the discovery of diverse tuft cell effector functions and associated feedback loops have also revealed the complexity of tuft cell biology. Although earlier work largely focused on extraintestinal tissues, novel genetic tools and recent mechanistic studies on intestinal tuft cells established fundamental concepts of tuft cell activation and functions. This Review is an overview of intestinal tuft cells, providing insights into their development, signalling and interaction modules in immunity and other states.</p>","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":null,"pages":null},"PeriodicalIF":65.1,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142321384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Justice, equity, diversity and inclusion in gastroenterology and hepatology 肠胃病学和肝病学的公正、公平、多样性和包容性
IF 45.9 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-26 DOI: 10.1038/s41575-024-00985-2
Nature Reviews Gastroenterology & Hepatology is launching a new Series on justice, equity, diversity and inclusion in an effort to increase awareness and advance equitable health.
Nature Reviews Gastroenterology & Hepatology 正在推出一个关于正义、公平、多样性和包容性的新系列,努力提高人们的认识,促进公平健康。
{"title":"Justice, equity, diversity and inclusion in gastroenterology and hepatology","authors":"","doi":"10.1038/s41575-024-00985-2","DOIUrl":"10.1038/s41575-024-00985-2","url":null,"abstract":"Nature Reviews Gastroenterology &amp; Hepatology is launching a new Series on justice, equity, diversity and inclusion in an effort to increase awareness and advance equitable health.","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":null,"pages":null},"PeriodicalIF":45.9,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41575-024-00985-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142317206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Disease prevention trials in IBD: feasibility to future outlook. IBD 疾病预防试验:从可行性到未来展望。
IF 65.1 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-20 DOI: 10.1038/s41575-024-00984-3
Sailish Honap,Nelly Agrinier,Silvio Danese,Laurent Peyrin-Biroulet
{"title":"Disease prevention trials in IBD: feasibility to future outlook.","authors":"Sailish Honap,Nelly Agrinier,Silvio Danese,Laurent Peyrin-Biroulet","doi":"10.1038/s41575-024-00984-3","DOIUrl":"https://doi.org/10.1038/s41575-024-00984-3","url":null,"abstract":"","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":null,"pages":null},"PeriodicalIF":65.1,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142275217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A resource for the food microbiome and its links with the human microbiome 有关食物微生物群及其与人类微生物群联系的资源。
IF 45.9 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-20 DOI: 10.1038/s41575-024-00993-2
Katrina Ray
{"title":"A resource for the food microbiome and its links with the human microbiome","authors":"Katrina Ray","doi":"10.1038/s41575-024-00993-2","DOIUrl":"10.1038/s41575-024-00993-2","url":null,"abstract":"","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":null,"pages":null},"PeriodicalIF":45.9,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142275221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Nature Reviews Gastroenterology &Hepatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1